Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Tarrytown, New York, founded in 1988. Its shares trade on Nasdaq under the ticker REGN, and the company is a member of both the S&P 500 and Nasdaq-100 indices.

The company discovers and develops drug candidates in its own laboratories. Eylea is a product used in eye diseases such as age-related macular degeneration. Dupixent, developed jointly with Sanofi, is used in immune-driven conditions such as atopic dermatitis and asthma. Libtayo is an immunotherapy medicine used in certain types of cancer, while Praluent is a cholesterol-lowering antibody. Many of the medicines rely on human antibodies derived from the company's genetically humanized mouse technology.

Those following Regeneron stock typically track clinical trial results, drug approval processes, the course of partnership agreements and the arrival of competing products on the market. On the REGN page at Lzzo.com the price is shown in US dollars, and a historical price chart and technical indicators appear on the same page.